2021 Annual Meeting: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Novel pathways and cancer dependencies as potential targets

2021 Annual Meeting: 603. Oncogenes and Tumor Suppressors: Basic: Aberrant signal strength and novel mechanisms in lymphoid and myeloid malignancies

2021 Annual Meeting: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Molecular Therapies in AML

2021 Annual Meeting: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Strategies to Overcome Resistance to BCL-2 Inhibition

2021 Annual Meeting: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Targets and Therapeutics

2021 Annual Meeting: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Agents

2021 Annual Meeting: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Mitochondrial Survival Pathways

2021 Annual Meeting: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, genetic and societal risk factors impacting ALL outcomes

2021 Annual Meeting: 613. Acute Myeloid Leukemia: Clinical and Epidemiological: COVID and beyond

2021 Annual Meeting: 613. Acute Myeloid Leukemia: Clinical and Epidemiological: Outcomes and Omics Potpourri

2021 Annual Meeting: 613. Acute Myeloid Leukemia: Clinical and Epidemiological: Practice-changing studies

2021 Annual Meeting: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies I

2021 Annual Meeting: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies II

2021 Annual Meeting: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Current approach to FLT3 mutated AML

2021 Annual Meeting: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Innovative induction regimens in AML: data from real life and clinical trials

2021 Annual Meeting: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Updates in treatment for high-risk AML

2021 Annual Meeting: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Targeted Therapies and Novel Therapies

2021 Annual Meeting: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Triplet Combinations of Novel Therapies

2021 Annual Meeting: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis

2021 Annual Meeting: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Modeling Novel Intracellular Mechanisms Contributing to Leukemogenesis

2021 Annual Meeting: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Response Prediction across the Spectrum of DNA, RNA, Protein and Ex Vivo Cells

2021 Annual Meeting: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Further unraveling the genetic background of AML

2021 Annual Meeting: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: New options of risk assessment and prediction of therapy response in AML

2021 Annual Meeting: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Mechanisms of Treatment Resistance

2021 Annual Meeting: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel therapeutic targets and pre-clinical studies

2021 Annual Meeting: 621. Lymphomas: Translational - Molecular and Genetic: Sequencing and Subtyping

2021 Annual Meeting: 621. Lymphomas: Translational—Molecular and Genetic: Clinical Applications

2021 Annual Meeting: 621. Lymphomas: Translational—Molecular and Genetic: Molecular Pathogenesis

2021 Annual Meeting: 622. Lymphomas: Translational–Non-Genetic: Lymphoma biology

2021 Annual Meeting: 622. Lymphomas: Translational–Non-Genetic: Lymphoma biology and microenvironment